Capital Fund Management (CFM)’s 10x Genomics TXG Stock Holding History

Capital Fund Management (CFM)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-76,493	Closed	-$894K	–	2677
2025 Q3	$894K	Sell	76,493 -218,695	-74%	-$2.85M	﹤0.01%	2147
2025 Q2	$3.42M	Buy	295,188 +20,727	+8%	+$189K	0.01%	1379
2025 Q1	$2.4M	Sell	274,461 -30,371	-10%	-$383K	0.01%	1341
2024 Q4	$4.38M	Buy	304,832 +81,164	+36%	+$1.28M	0.01%	1143
2024 Q3	$5.05M	Buy	+223,668	New	+$4.62M	0.01%	1020
2024 Q2	–	Sell	-20,187	Closed	-$758K	–	2184
2024 Q1	$758K	Buy	+20,187	New	+$887K	﹤0.01%	1784
2021 Q4	–	Sell	-23,833	Closed	-$3.47M	–	1866
2021 Q3	$3.47M	Buy	+23,833	New	+$4.09M	0.03%	719

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s TXG Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 76,493 shares — an estimated $894K sold.

Capital Fund Management (CFM) first reported a position in TXG in Q3 2021 and held it in 7 quarters. The position peaked at $5.05M in Q3 2024. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Capital Fund Management (CFM) reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 76,493 10x Genomics shares in Q4 2025, an estimated $894K.
Capital Fund Management (CFM) first reported a position in 10x Genomics in Q3 2021 and held it in 7 quarters.
Capital Fund Management (CFM)'s 10x Genomics position peaked at $5.05M in Q3 2024.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.